Mesna Baxter Healthcare (Mesna)

Mesna releases sulfhydryl groups that bind directly to acrolein, the urotoxic by‑product of cyclophosphamide and ifosfamide metabolism. This chemical conjugation creates a harmless compound that is eliminated in the urine, preventing acrolein from damaging the bladder lining and thereby averting hemorrhagic cystitis.

The specific dose and schedule of Mesna are determined by the prescribing clinician based on the chemotherapy regimen, patient weight, renal function, and treatment protocol. Healthcare providers calculate the appropriate amount to ensure effective protection while minimizing potential adverse effects.

Safety data for Mesna in pregnancy and lactation are limited, and the product carries an unknown pregnancy category. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Mesna is the standard uroprotective agent specifically designed to detoxify acrolein, the metabolite responsible for chemotherapy‑induced bladder toxicity. Alternative agents, such as sodium thiosulfate, target different toxic metabolites and are used for other chemotherapeutic drugs. Mesna’s direct binding mechanism makes it the preferred choice for cyclophosphamide and ifosfamide regimens.

Mesna should be stored at ambient temperature, below 25 °C, in its original container. Keep the product away from moisture, direct sunlight, and excessive heat to maintain stability and potency throughout its shelf life.

Mesna is administered orally in tablet or liquid form, typically taken at specific intervals before, during, and after chemotherapy infusion. The exact timing and frequency are prescribed by the treating oncologist to align with the chemotherapy schedule and ensure optimal uroprotection.

The most serious risks include severe allergic reactions such as anaphylaxis, significant hematuria, and acute renal failure. Patients should be monitored for signs of hypersensitivity, blood in urine, or sudden loss of kidney function, and medical attention should be sought immediately if these occur.

Mesna is contraindicated in patients with known hypersensitivity to the drug or any of its components. Caution is also advised for individuals with severe renal impairment where the drug’s clearance may be compromised, and it should be avoided in patients where the risk of allergic reaction outweighs the benefit.